Related Experiment Video
Updated: Jul 4, 2026
12:59
Improving Strength, Power, Muscle Aerobic Capacity, and Glucose Tolerance through Short-term Progressive Strength Training Among Elderly People
Published on: July 5, 2017
Myasthenia gravis in the elderly: Is it different?
1Department of Neurology, University of Bergen, Bergen, Norway. Johan.Aarli@nevro.uib.no
Annals of the New York Academy of Sciences
|June 24, 2008
Summary
Myasthenia gravis (MG) is increasingly diagnosed in individuals over 50. Ocular symptoms can be missed in older adults, and titin antibodies are more common in late-onset, non-thymoma MG.
Area of Science:
- Neurology
- Immunology
- Geriatrics
Background:
- Myasthenia gravis (MG) diagnosis is increasing, particularly in patients over 50.
- Ocular symptoms of MG can be challenging to diagnose in the elderly due to age-related changes.
- Thymomatous MG is more prevalent in older individuals, with onset typically between 50-60 years.
Purpose of the Study:
- To define and characterize late-onset myasthenia gravis (MG) in the elderly.
- To investigate the diagnostic challenges and immunological differences in elderly MG patients.
- To explore the role of thymoma and autoantibodies in late-onset MG.
Main Methods:
- Review of recent data on MG diagnosis and prevalence in different age groups.
- Analysis of clinical presentation, focusing on ocular symptoms in the elderly.
- Examination of thymus pathology and autoantibody profiles (AChR, titin) in relation to age of onset and thymoma status.
Main Results:
- MG onset after 50 years is increasingly diagnosed, while early-onset prevalence remains stable.
- Ocular symptoms like ptosis and diplopia are more difficult to detect in the elderly.
- Late-onset MG shows a higher prevalence of thymoma and titin antibodies compared to early-onset MG. Mean AChR antibody concentration is lower in elderly MG patients.
Conclusions:
- Late-onset myasthenia gravis presents unique diagnostic challenges, particularly with ocular symptoms.
- Immunological profiles, including autoantibody presence (titin), differ between early-onset and late-onset MG.
- Age-related changes and genetic factors may influence MG presentation and antibody responses in the elderly.
Related Concept Videos
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:15Myasthenia Gravis: Diagnostic Tests
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
01:22Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
01:28Disorders of the Skeletal Muscle
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
01:26Chemical Synapses
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
01:26Chemical Synapses
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...